{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.50","value":"0.4"},{"groupId":"OG001","spread":"3.13","value":"3.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"63"}],"units":"Participants"}],"description":"The maximum duration for which a participant continuously maintained a platelet count \\>=50 Gi/L was calculated and summarized for the first 12 weeks of Part 1. Participants with non-weekly assessments were assumed to have maintained a positive response for each week between two assessments that had positive responses. If a participant achieved a positive response at an assessment and then achieved a negative response at the next assessment, then it was assumed that the participant had achieved a positive response for one day.","dispersionType":"Standard Deviation","groups":[{"description":"In Part 1, participants aged between 6 and 17 years with a body weight \\<27 kg received placebo 37.5 mg QD, and those with a body weight \\>=27 kg received placebo 50 mg QD. Participants of East Asian ancestry received a starting dose of placebo 25 mg QD. Participants aged between 1 and 5 years received placebo 1.2 mg/kg QD; participants of East Asian ancestry received a starting dose of placebo 0.8 mg/kg/day.","id":"OG000","title":"Part 1 (Randomized Period)-Placebo"},{"description":"In Part 1, participants aged between 6 and 17 years with a body weight \\<27 kg received eltrombopag 37.5 mg QD, and those with a body weight \\>=27 kg received eltrombopag 50 mg QD. Participants of East Asian ancestry received a starting dose of eltrombopag 25 mg QD. Participants aged between 1 and 5 years received eltrombopag 1.2 mg/kg QD; participants of East Asian ancestry received a starting dose of eltrombopag 0.8 mg/kg/day.","id":"OG001","title":"Part 1 (Randomized Period) - Eltrombopag"}],"paramType":"MEAN","populationDescription":"ITT Population","reportingStatus":"POSTED","timeFrame":"From Baseline up to Week 12 of Part 1","title":"Maximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During the First 12 Weeks of Part 1","type":"SECONDARY","unitOfMeasure":"Weeks"}